Dr. Karng S. Log, DO
Hematology & Oncology (Hematology & Oncology Physician)
7780 S Broadway, Suite 380
Littleton, CO 80122
Who else practices at this address →
Arapahoe County includes primary care (8% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 277
Licensed in Colorado since 2011, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license 50124 (first issued 2011; transferred to compact physician) · MI license 5101016452
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Intermountain Health Lutheran Hospital Wheat Ridge, CO
- Saint Joseph Hospital Denver, CO
Medical groups
- Intermountain Medical Group Denver LLC (568 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 277
- Services billed
- 601
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 418 | 182 |
| Established patient office or other outpatient visit, 20-29 minutes | 125 | 107 |
| Established patient office or other outpatient visit, 40-54 minutes | 51 | 37 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Littleton, CO | 90 |
| Anastrozole Other prescribers in Littleton, CO | 74 |
| Dexamethasone Other prescribers in Littleton, CO | 65 |
| Eliquis (apixaban) Other prescribers in Littleton, CO | 62 |
| Xarelto (rivaroxaban) Other prescribers in Littleton, CO | 60 |
| Prochlorperazine Maleate Other prescribers in Littleton, CO | 57 |
| Tamoxifen Citrate Other prescribers in Littleton, CO | 47 |
| Olanzapine Other prescribers in Littleton, CO | 45 |
| Letrozole Other prescribers in Littleton, CO | 44 |
| Imbruvica (ibrutinib) | 42 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $378 in total to this clinician.
| Janssen Biotech, Inc. | $199 |
|---|---|
| Tempus Ai, Inc | $108 |
| Argenx US, Inc. | $55.50 |
| Iovance Biotherapeutics, Inc. | $16.31 |
| Food and Beverage | $223 |
|---|---|
| Education | $155 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 5, 2025 | Education RYBREVANT · Oncology · in-kind | $99.99 |
| Argenx US, Inc. Mar 12, 2025 | Education in-kind | $55.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $315,969 in research payments for these studies, mostly to the institutions running them.
- A phase 2,open label study to evaluate the safety,tolerability,pharmacokinetics,immunogenicity,and antitumor activity of volrustomig priming regimen in combination with other anticancer agents in participants with sol…
AstraZeneca UK Limited - A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrolizumab with or without maintenance MK 2870 in the First-line Treatment of Metastatic Squamous Non…
Merck Sharp & Dohme LLC - An interventional openlabel randomized multicenter phase 3 study of PF07220060 plus letrozole compared to CDK46 inhibitor plus letrozole in participants over 18 years of age with hormone receptor hrpositive HER2NEGATI…
Pfizer Inc. - M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants Wit…
AbbVie Inc. - M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult P…
AbbVie Inc. - An observational,prospective,multicenter study of non small cell lung cancer patients in the US receiving standard of care and initiating an approved therapy with risk of pneumonitis ILD
AstraZeneca UK Limited - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06508658 - A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat MK-3543 versus Hydroxyurea in Cytoreductive Therapy Na ve Essential Thrombocythemia P…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.